[Nucleophosmin mutations in hematological malignancies - review].

Abstract

Nucleophosmin (NPM) is a protein that shuttles between the nucleus, nucleoplasm and cytoplasm. NPM gene mutations and aberrant cytoplasmic NPM localization have been recently described in acute myelogenous leukemia (AML) with normal karyotype and in a few myelodysplastic syndromes. Expression of NPM mutant reduces the ability of Arf to initiate a p53 response and to induce cell cycle arrest. Clinical research has revealed that NPM mutations are relative to prognosis and can be used to monitor and quantify minimal residual disease (MRD) in AML patients with normal karyotype, therefore, these findings indicate that nucleophosmin mutations might contribute to illustration of myeloid leukemogenesis. In this paper, the research progress of nucleophosmin mutations in haematological malignancies was reviewed.

• Authors: Zhan-Peng Luo, Ling Zhang
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 15 Issue 3 Pg. 662-6 (Jun 2007) ISSN: 1009-2137 [Print] China
• PMID: 17605889 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• NPM1 protein, human
• Nuclear Proteins
• Nucleophosmin
• FLT3 protein, human
• fms-Like Tyrosine Kinase 3

Topics

• Cell Nucleolus (metabolism)
• Hematologic Neoplasms (genetics, pathology)
• Humans
• Mutation
• Nuclear Proteins (genetics)
• Nucleophosmin
• fms-Like Tyrosine Kinase 3 (genetics)